Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 19/20 | 0.74 |
| ▸ | CYP11B1 | P15538 | 16/20 | 0.74 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20338281 | 0.85 | CYP11B2 (1.00) | CYP11B2CYP11B1 | |
| SCHEMBL20340027 | 0.85 | CYP11B2 (0.70) | CYP11B2CYP11B1GABRG2GABRB3GABRA5 | |
| SCHEMBL20340213 | 0.84 | CYP11B2 (0.72) | CYP11B2CYP11B1 | |
| SCHEMBL20340150 | 0.84 | CYP11B2 (0.71) | CYP11B2CYP11B1 | |
| SCHEMBL20339865 | 0.83 | CYP11B1 (0.70) | CYP11B2CYP11B1 | |
| SCHEMBL20340190 | 0.79 | CYP11B2 (0.70) | CYP11B2CYP11B1 | |
| SCHEMBL20340104 | 0.78 | CYP11B2 (0.71) | CYP11B2CYP11B1 | |
| SCHEMBL20340044 | 0.78 | CYP11B2 (0.69) | CYP11B2CYP11B1 | |
| SCHEMBL20340004 | 0.78 | CYP11B2 (0.53) | CYP11B2CYP11B1 | |
| SCHEMBL20340204 | 0.77 | CYP11B2 (0.70) | CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562487-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Selenity Therapeutics (Bermuda), Ltd. (BM) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018125800-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-07-05 | — | — | WO | disclosed |